Bristol-Myers Squibb and Otsuka Pharmaceuticals have paid $534 million to settle thousands of Abilify lawsuits alleging the antipsychotic medication caused compulsive gambling and other impulse control disorders. The pharmaceutical companies reached a confidential settlement in February 2019 to resolve more than 2,500 federal cases consolidated in Florida, along with state cases in California and New Jersey. Plaintiffs claimed the drugmakers knew about the gambling risks for years””evidenced by warnings on European and Canadian labels””but failed to adequately warn American patients and doctors until the FDA intervened in 2016.
A typical plaintiff in these cases was someone prescribed Abilify for conditions like depression, bipolar disorder, or schizophrenia who then developed an uncharacteristic and destructive gambling habit. Some patients reported losing their life savings, homes, and marriages to compulsive gambling that began only after starting the medication and stopped after discontinuing it. The settlement did not include any admission of liability by the defendants, which is standard in pharmaceutical mass tort resolutions. This article covers the full timeline of Abilify litigation, the FDA warnings that sparked the lawsuits, how settlements were structured in both the United States and Canada, and what options may remain for those affected by Abilify’s side effects.
Table of Contents
- What Were the Abilify Gambling Lawsuit Settlement Amounts?
- The FDA Warning That Changed Everything
- Canadian Abilify Class Action Settlement
- How the Abilify MDL Process Worked
- Who Qualified for the Abilify Settlement?
- The Difference Between MDL Settlements and Class Actions
- Current Status and Future Outlook
- Conclusion
What Were the Abilify Gambling Lawsuit Settlement Amounts?
The total known settlement value for Abilify gambling litigation in the United States is $534 million, paid by Bristol-Myers Squibb to resolve thousands of individual lawsuits. The first settlements came in April 2018, when the companies quietly resolved three bellwether cases that had been scheduled for trial the following month. Bellwether trials serve as test cases in mass tort litigation, and their outcomes””or pre-trial settlements””often signal how the broader litigation will resolve. The amounts paid in those initial three cases were never disclosed. By February 2019, a comprehensive confidential settlement was reached covering all federal cases in MDL 2734 in the Northern District of Florida, plus state court cases pending in California and New Jersey.
Because the settlement was confidential, individual payment amounts were not publicly released. However, in pharmaceutical mass torts, settlement amounts typically vary based on factors like the severity of documented harm, the strength of medical evidence linking the drug to the injury, and how long the plaintiff took the medication. Beyond the civil litigation, Bristol-Myers Squibb also faced government enforcement actions. In December 2016, the company paid $19.5 million to settle allegations with the U.S. Justice Department over unlawful marketing of Abilify. The company had previously been fined $515 million by the Justice Department for off-label marketing practices, demonstrating a pattern of regulatory issues that likely strengthened plaintiffs’ negotiating position in the civil cases.
The FDA Warning That Changed Everything
On May 3, 2016, the FDA issued a safety communication that became the cornerstone of Abilify litigation: the agency warned that Abilify was associated with compulsive gambling, binge eating, hypersexuality, and compulsive shopping. This warning was based on 184 cases of impulsive behaviors reported to the FDA’s adverse event reporting system between 2002 and January 2016, with 164 of those cases specifically involving gambling. Of the total reported cases, 167 occurred in the United States. The central allegation in the lawsuits was not simply that Abilify caused gambling problems, but that the manufacturers knew about this risk and failed to warn American patients. European and Canadian Abilify labels already included warnings about “pathological gambling” before the FDA took action. plaintiffs argued this discrepancy proved the companies were aware of the risk but made a business decision not to update U.S.
labels voluntarily. By August 2016, compulsive behavior warnings were finally added to American Abilify labels””but for many patients, the damage was already done. However, proving causation in individual cases presented challenges. Not every patient who gambled compulsively while taking Abilify could definitively attribute that behavior to the medication. Defense attorneys argued that some plaintiffs had pre-existing gambling tendencies or other factors contributing to their behavior. strong cases typically involved patients with no gambling history who developed sudden, severe gambling problems after starting Abilify and whose behavior normalized after stopping the drug.
Canadian Abilify Class Action Settlement
Canadian patients affected by Abilify received a separate settlement through class action litigation. In late 2024 and early 2025, courts in Ontario and Quebec approved a CDN $14,750,000 settlement””approximately $14.75 million Canadian dollars””to resolve claims against the drug manufacturers. The Ontario Superior Court of Justice approved the settlement on December 23, 2024, followed by Quebec Superior Court approval on February 7, 2025. The Canadian settlement covers a specific class: individuals who took Abilify before February 23, 2017, or who received Abilify Maintena injections between February 6, 2014, and December 16, 2016. Class counsel fees of $4.43 million plus disbursements and taxes were approved, representing eight years of legal work on the case.
The claims deadline for the Canadian settlement is November 12, 2025, giving eligible class members time to submit documentation. The Canadian class action illustrates an important limitation of the U.S. settlement: it only resolved American claims. Patients in other countries where Abilify was marketed faced different legal landscapes and timelines. For Canadian claimants who missed the U.S. litigation entirely, the domestic class action provided an alternative path to compensation, albeit at a smaller total amount reflecting the smaller affected population.
How the Abilify MDL Process Worked
Federal Abilify lawsuits were consolidated into MDL 2734, officially titled “In re: Abilify (Aripiprazole) Products Liability Litigation,” in the Northern District of Florida. Multidistrict litigation consolidation is a procedural tool used when many similar lawsuits are filed across the country. Rather than having hundreds of judges independently handling pretrial matters, one judge oversees discovery, motions, and other preliminary proceedings for all cases. By February 2019, more than 2,500 lawsuits had been filed in the MDL. Bristol-Myers Squibb and Otsuka Pharmaceuticals were named as co-defendants in virtually all cases.
The MDL process allowed plaintiffs’ attorneys to share resources and build a comprehensive evidentiary record about what the companies knew and when they knew it. Internal company documents obtained through discovery proved crucial to establishing that manufacturers had access to the same adverse event data that eventually prompted the FDA warning. The settlement of bellwether cases in April 2018 effectively ended the litigation before any trial verdicts were rendered. This is a common outcome in pharmaceutical MDLs””once both sides have tested their arguments through bellwether preparation, they often have enough information to negotiate a global resolution. For plaintiffs, settlement provided guaranteed compensation without the risk of losing at trial. For defendants, it capped their liability and ended ongoing litigation costs.
Who Qualified for the Abilify Settlement?
Eligibility for the Abilify settlement generally required plaintiffs to demonstrate they took Abilify, developed compulsive behaviors (particularly gambling) during treatment, and suffered documented financial or personal harm as a result. Strong cases featured medical records showing Abilify prescriptions, financial records documenting gambling losses, and ideally testimony from treating physicians who observed the behavioral changes. The settlement favored plaintiffs who could establish a clear temporal connection between Abilify use and gambling behavior. Someone who started gambling heavily six months after beginning Abilify and stopped gambling shortly after discontinuing the medication presented a more compelling case than someone with a more ambiguous timeline.
Plaintiffs who had documented gambling problems before taking Abilify faced significant hurdles, though defense arguments about pre-existing conditions did not automatically disqualify claims. A significant limitation affects anyone learning about this litigation now: attorneys are generally no longer accepting new Abilify lawsuit cases related to the original MDL. The settlement process has concluded, and the window for filing claims has closed. Those who suffered harm but never filed suit during the active litigation period have likely lost their opportunity for compensation through this particular legal avenue, though they should consult with an attorney about their specific circumstances and any applicable statutes of limitations.
The Difference Between MDL Settlements and Class Actions
The Abilify litigation in the United States was not technically a class action””it was a mass tort consolidated through the MDL system. This distinction matters for understanding how compensation worked. In a class action, one or more named plaintiffs represent an entire class, and any settlement automatically applies to all class members unless they opt out. In mass tort MDLs, each plaintiff files an individual lawsuit and must individually agree to any settlement terms. The Canadian Abilify resolution, by contrast, was a true class action.
This meant that eligible class members who did not opt out were automatically bound by the settlement terms and could submit claims through the established process. The CDN $14.75 million settlement fund will be distributed among claimants based on criteria established in the settlement agreement, with individual payments depending on how many claims are filed and the documented severity of each claimant’s harm. This structural difference explains why U.S. settlement amounts varied by plaintiff while Canadian claimants will receive payments from a common fund. Neither approach is inherently better””MDL settlements can result in higher payments for plaintiffs with strong individual cases, while class actions ensure broader participation and administrative efficiency.
Current Status and Future Outlook
As of 2025, the primary Abilify gambling litigation has concluded. The February 2019 settlement resolved the vast majority of pending U.S. cases, and the recent Canadian court approvals have addressed claims in that jurisdiction. Bristol-Myers Squibb’s $534 million in total U.S. settlements represents one of the larger pharmaceutical liability payouts for impulse control side effects, establishing important precedent for how such cases are valued.
The Abilify litigation’s legacy extends beyond the specific settlement amounts. The FDA’s 2016 warning and subsequent label changes have made compulsive behavior risks more visible for patients taking aripiprazole and similar medications. For the pharmaceutical industry, the litigation reinforced that failing to update U.S. labels to match warnings already present on international labels creates significant legal exposure. Future cases involving similar cross-border labeling discrepancies will likely cite the Abilify precedent.
Conclusion
The Abilify gambling lawsuit settlements totaling $534 million in the United States, plus CDN $14.75 million in Canada, compensated thousands of patients who developed compulsive gambling and other impulse control disorders while taking the antipsychotic medication. The litigation centered on allegations that Bristol-Myers Squibb and Otsuka Pharmaceuticals knew about gambling risks””as evidenced by warnings on European and Canadian labels””but failed to warn American patients until the FDA forced the issue in 2016. For those affected by Abilify side effects who did not participate in the original litigation, options are now limited.
The U.S. MDL has concluded, and attorneys are generally not accepting new cases. Canadian residents may still have until November 12, 2025, to file claims in that class action if they meet the eligibility criteria. Anyone uncertain about their legal options should consult with a pharmaceutical litigation attorney to discuss their specific situation and any remaining avenues for potential compensation.